News from Quintiles, Dell and CytomX – People on the move
Quintiles has named Steven Skolsky as its new leader of its clinical and data operations (CDO) unit.
As global head of the unit Skolsky will take charge of 5000 employees, and will work to unite the firm’s clinical data management with its clinical operations.
Prior to Quintiles, he was principal at strategic life science consultancy company Expis Partners.
Skolsky commented: “Biopharma companies are looking for an ally who can bring innovative solutions to the table that increasse the speed and quality of clinical research.
“I am pleased to lead Quintiles’ clinical and data operations unit as we ally with customers to leverage new processes and cutting-edge technologies, like Quintiles Infosario, to transform clinical research and make informed drug development decisions.”
Andrew Litt has become Dell’s new chief medical officer for its healthcare and life sciences services.
The former head of Litt Healthcare Ventures will be responsible for providing strategic insight to Dell's healthcare solutions to promote the benefits of information-enabled healthcare.
August Calhoun, VP of the firm’s healthcare and life sciences services said: “Currently, our team includes hundreds of clinicians along with business and technology professionals who specialize in clinical and IT implementation.
“Andy will help our team drive further performance efficiencies and healthcare transformation with our customers.”
CytomX Therapeutics has appointed Henry Lowman as their new chief scientific officer.
Lowman comes to the role after joining CytomX in September 2010, as VP of research.
In his new role, he will lead research and development activities to advance the proteolytically-activated antibodies specialists’ Probody candidates.
“Henry’s tremendous depth of experience in antibody engineering and therapeutic development has enabled him to make unique contributions to CytomX over the past year,” said Sean McCarthy, D. Phil., chief executive officer of CytomX.
“His previous successes in the engineering of high value clinical candidates and marketed products will continue to prove invaluable as we gain even greater momentum with the Probody platform.”
Lundbeck has drafted Kristian Sibilitz, Christian Houborg and Lene Andersen in as VPs supply operations and engineering.
New VP of logistics Sibilitz began at Lundbeck in 2005 as a replenishment planner in logistics.
Houborg – who joined the company in 2002 – was recently named divisional director for service and technical operations. He now takes the position of VP, services and technical operations.
And Lene Andersen started Lundbeck 16 years ago as a section leader in QC, before moving up the ranks to become VP of quality supply operations.
The firm says its new team, all promoted from within the business, will prepare it for multiple launches in the pipeline over the next few years.
vivoPharm has named Ian Nisbet as the new chairman of its board of directors.
He is also a founder and partner in biotech consultancy firm Afandin.
Nisbet said he is now ready to take on the challenge of establishing the Australian-based company’s presence in the US.
Ralf Brandt, vivoPharmʼs founder, CEO and Managing Director added: “It is a privilege for our company to leverage the networks and experience of someone of Ianʼs caliber to help us navigate the very exiting times ahead.”
Swiss API makers Carbogen Amcis has named Pascal Villemagne as commercial vice president.
Villemagne will lead the company’s overall sales and marketing operations, and will serve on the company’s executive management team.
Prior to joining Carbogen, he served as VP, contract manufacturing, at Farmhispania, an API contract manufacturing company based in Spain.
Of his new position he said: “I look forward to expanding the company’s regional sales and marketing strategies and to helping clients make critical decisions in drug development and commercialization more efficiently.”
